
Objective To assess the safety of recombinant equine lubricin (rEqLub) injections in healthy equine fetlocks using clinical, biochemical, and histological outcomes. Methods 6 adult horses were enrolled (3geldings, 3mares) in a block randomized, controlled experimental study. All 24 fetlocks were assigned to receive an injection of either 2 mL rEqLub (1mg/mL) or PBS at 1 of 3 time points. Recombinant equine lubricin was injected into a randomized forelimb at 28 days and 1 day prior to study completion, and rEqLub and PBS were injected into contralateral hindlimbs at 7 days prior to study completion. Clinical and orthopedic examinations were performed at baseline and prior to and 1 day following each injection; synovial fluid was collected for biochemistry, flow cytometry, and proteomics; synovial membrane and osteochondral sections were collected from day-28 rEqLub-treated joints and scored using Osteoarthritis Research Society International criteria. Results 3 sequential IA injections of rEqLub in 3 different healthy fetlocks were well tolerated and did not result in adverse clinical or histologic outcomes. There were no differences in clinical or synovial fluid biochemical parameters between rEqLub- and PBS-injected joints. Synovial fluid WBC concentrations and total protein were increased 1 day after injection in rEqLub-treated joints. Conclusions IA rEqLub did not cause any detectable clinical, biochemical, or histological adverse effects, supporting the favorable tolerability and safety profile of rEqLub. The small sample size and multijoint design are limitations. Clinical Relevance rEqLub injections were well tolerated, establishing a basis for future equine efficacy trials to evaluate the ability of recombinant lubricin to mitigate osteoarthritis in a clinically relevant equine model.
Abstract Objective To investigate the protective effects and molecular mechanisms of heat-inactivated Bifidobacterium adolescentis LA-20 (HT-LA20) against doxorubicin (DOX)-induced senescent injury in feline intestinal epithelial cells (FIECs). Methods This in vitro experimental study was conducted from November 1, 2025, through August 31, 2026, and involved only FIECs. No clinical patients or animals were included. The DOX-induced injury and senescence model was established in FIECs. The effects of HT-LA20 on cellular senescence and related proteins were evaluated by senescence-associated β-galactosidase staining, cell viability assays, and ELISA. Transcriptomic sequencing and untargeted metabolomics were integrated to elucidate the molecular regulatory mechanisms. Results Cell-based assays and transcriptomic and untargeted metabolomic analyses were performed with 4 independent biological replicates/group. HT-LA20 reversed DOX-induced reductions in cell viability and cellular senescence; upregulated tight junction proteins and mucins 1 and 2; suppressed release of IL-1β, tumor necrosis factor–α, IL-8, monocyte chemoattractant protein 1, and matrix metalloproteinase 1; and promoted VEGF and basic fibroblast growth factor (bFGF) secretion. Transcriptomic and metabolomic analyses showed that HT-LA20 reversed DOX-induced omic disturbances. Integrated multiomics Kyoto Encyclopedia of Genes and Genomes enrichment analysis indicated that its effects centered on the retinol metabolism–serotonergic synapse–intestinal immunoglobulin A immune network multitarget axis and regulation of inflammatory pathways, including nuclear factor κ B and Toll-like receptor signaling. Conclusions HT-LA20 effectively alleviates DOX-induced injury in FIECs by restoring intestinal epithelial barrier function and suppressing inflammatory senescence. Clinical Relevance These findings provide a theoretical basis for subsequent in vivo studies on postbiotics for chemotherapy-induced intestinal injury in veterinary medicine; clinical application requires further validation.
Abstract Objective To characterize echocardiographic findings of right heart and pulmonary artery remodeling in dogs with heartworm disease. Methods Medical records were searched for those of client-owned dogs with heartworm infection diagnosed from July 2020 through February 2023 and with no major systemic diseases not attributable to heartworm infection. Results for variables of interest were compared for dogs grouped by heartworm clinical class (classes 1 and 2 [mild] vs classes 3 and 4 [advanced]), pulmonary hypertension probability (low and intermediate vs high), and tricuspid regurgitation pressure gradient (mild, moderate, or severe). Pre- and postextraction variables were also compared for dogs with caval syndrome. Results 44 dogs were included. Compared with dogs with mild heartworm disease (n = 23), dogs with advanced heartworm disease (21) had greater right atrial and right ventricular enlargement, less right pulmonary artery distensibility, shorter pulmonary artery acceleration time, higher main pulmonary artery-to-aorta ratio, and lower right ventricular systolic function. Similar results were identified for dogs with high (vs intermediate or low) pulmonary hypertension probability. Normalized right atrial diameter had the highest discriminatory performance for identifying advanced heartworm disease (area under the curve, 0.95; 95% CI, 0.88 to 1.00), followed by tricuspid regurgitation pressure gradient, normalized right ventricular dimension, and other variables. Right atrial size significantly decreased after heartworm extraction (n = 8 dogs). Conclusions Advanced heartworm disease is associated with marked right heart and pulmonary artery remodeling. Clinical Relevance Echocardiographic assessment of right heart remodeling may assist clinicians in evaluating heartworm disease severity and identifying dogs with clinically important cardiopulmonary involvement.
Abstract Objective To describe the elimination kinetics of NSAIDs during carbon hemoperfusion (cHP) in dogs with toxicosis, specifically the apparent elimination rate constant, half-life, and plasma reduction. Methods 19 client-owned dogs (median age, 2.5 years; median body weight, 22 kg) with ibuprofen (n = 10), carprofen (5), or naproxen (4) toxicosis treated with cHP at 2 academic veterinary teaching hospitals from November 30, 2022, through July 7, 2024. Dogs were presented after known or suspected ingestion at median estimated maximum doses of 720, 200, and 325 mg/kg for ibuprofen, carprofen, and naproxen, respectively. The median interval from ingestion to cHP was 6.8 hours. Plasma concentrations were measured by LC-MS-MS in-serial samples collected during and, when available, after cHP. Results The median total plasma reduction was 58% (IQR, 51 to 80). The overall half-life during cHP was 1.3 hours (IQR, 1.1 to 1.8) by the 2-point method, concordant by regression (1.4 hours), and approximately 3.7-, 5.4-, and 52.0-fold shorter than respective therapeutic-dose half-lives. Among 5 dogs with posttreatment samples, plasma concentration rebounded after cHP in 1 naproxen-treated dog. The cHP-associated rate constant exceeded the intrinsic rate constant 11- to 40-fold in 4 of 5 dogs. Conclusions Carbon hemoperfusion was associated with substantial reductions in plasma NSAID concentrations during treatment in dogs with severe ibuprofen, carprofen, or naproxen toxicosis. Most of the decline occurred early in the session. Further studies are warranted to optimize treatment protocols. Clinical Relevance Carbon hemoperfusion markedly shortened NSAID elimination half-lives in dogs with severe toxicosis, accelerating removal well beyond endogenous elimination.